LINKS
ABOUT
SOCIAL

kernal@kernalbio.com

Tel: 857-600-0762

700 Main Street, North
Cambridge, MA 02139 

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Google+ Icon

© 2018 by Kernal Biologics, Inc. 

Onco-selective mRNA immunotherapy

TECHNOLOGY

01

Precise engineering

02

Fully Selective

Kernal's synthetic biology-based approach includes the development of a platform using deep learning algorithms and big data to create better designed mRNAs.

Smart engineering makes our mRNAs fully selective for cancer cells, they have zero expression in healthy cells. 

03

Stealthy mRNA

Our proprietary design and manufacturing processes enable the evasion of RNA sensors, particularly for repetitive applications. 

MEET KERNAL

 
 

SUPPORTERS & MEMBERSHIPS

Memberships
kernal biologics

Boston 2018 Winner

2019 Spring Cycle

Supporters
 
 

NEWS FROM US

Kernal team has access to industry experts and veterans for mentorship and advice

MassBio® Welcomes Four Life Sciences Startups to Participate in MassCONNECT® Spring Mentorship Cycle. Kernal is among the companies that was selected for the 2019 Spring program.
 

Kernal's disruptive mRNA 2.0 technology gets more recognition

Kernal gets a second award from Amgen, the Biotech giant that pioneered BiTE® immunotherapy and T-VEC (Imlygic™), the first oncolytic virus therapy approved by the FDA. 

Kernal Biologics receives Technology in Space Award from CASIS & Boeing through MassChallenge

The award will allow Kernal team to work with NASA scientists to screen and validate Kernal's onco-selective mRNAs in the International Space Station under micro-gravity conditions. This study will further de-risk our platform for clinical development. 

1 / 3

Please reload

STAY IN TOUCH